Drugs / BIZALIMOGENE RALAPLASMID
BIZALIMOGENE RALAPLASMID
Trials 10 · a red edge is where a trial was stopped
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIZALIMOGENE RALAPLASMID | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297247 ↗ |
| Known as | Bizalimogen ralaplasmido | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297247 ↗ |
| Known as | Bizalimogene ralaplasmide | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297247 ↗ |
| Known as | PGX-3002 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297247 ↗ |
| Known as | VGX 3100 | “VGX-3100 is an investigational DNA-based immunotherapy being developed as an alternative to surgery and ablation for cervical High-Grade Squamous Intraepithelial Lesion (HSIL)...” PMID 33175656 ↗ Nov 202010“6 mg of VGX-3100 (2 separate DNA plasmids respectively encoding E6 and E7 proteins of HPV 16 and HPV 18)” NCT02163057 ↗ “INO-3112 i.e. the combination of VGX-3100 and INO-9012, specifically:” NCT02501278 ↗ “Biological: VGX 3100” NCT01304524 ↗ |
| Modality | Vaccine | “VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins” PMID 26386540 ↗ Sep 2015 |
| Route | Intramuscular | “given intramuscularly at 0, 4, and 12 weeks” PMID 26386540 ↗ Sep 2015 |